RELMADA THERAPEUTICS, INC. - 8-K Filing

Relmada Therapeutics appoints Bipin Dalmia as Chief Business Officer to advance NDV-01 and support long-term growth (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $RLMD

Read the full article at SEC EDGAR

More Regulatory news